Wu, Y., Zeng, F., Zhao, Y
A systematic review found that combining GLP-1 receptor agonist therapy with structured exercise programs led to greater weight loss compared to medication alone
Tirzepatide, the first approved dual GIP/GLP-1 receptor agonist, is a 39-amino acid peptide with an approximately 120-hour half-life supporting once-weekly dosing
This discussion should address: Your specific diabetes control needs and whether alternative medications could provide adequate glycemic management The infant's health status , as premature or medically fragile infants may warrant more conservative medication approaches Your breastfeeding goals , including whether you plan exclusive breastfeeding or combination feeding Monitoring strategies for both maternal blood sugar control and infant growth and development Contact your healthcare provider if you experience severe or persistent side effects while taking any diabetes medication during lactation, including nausea, vomiting, diarrhea, or signs of hypoglycemia (shakiness, sweating, confusion)
Skin loses its elasticity when fat disappears quickly, leaving loose tissue that diet and exercise struggle to correct